Tiny virus may hold key to kidney cancer treatment success
NCT ID NCT07018037
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study is looking at whether levels of a common virus called TTV can help predict how well immunotherapy works in people with advanced kidney cancer. Researchers will measure TTV levels in 20 patients before and during their first immunotherapy treatment. The goal is to see if the virus could serve as a simple biomarker to guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to predict which kidney cancer patients will benefit from immunotherapy.
- What could go wrong
- This is a very small pilot study (20 people) that only observes virus levels, not treatment outcomes. It may not find a clear link or be too early to guide treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
"Regina Elena" National Cancer Institute
RECRUITINGRome, Rome, 00144, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?